CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
继发性中枢神经系统淋巴瘤合并 COVID-19 感染患者自体干细胞移植后成功接受 CD19 CAR-T 细胞治疗：病例报告及文献综述
英文原题：Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review.
查看英文原题
Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文报告一例64岁继发性中枢神经系统淋巴瘤（sCNSL）患者：其在自体干细胞移植（ASCT）后接受CD19CAR-T 细胞治疗期间感染COVID-19。研究结果表明，即使对于SARS-CoV-2阳性的免疫功能低下淋巴瘤患者，ASCT联合CAR-T 治疗sCNSL也可能可行。
展开英文摘要原文
This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT). Our findings demonstrate that the combination of ASCT and CAR-T for sCNSL may be feasible, even for SARS-CoV-2-positive immunocompromised lymphoma patients.
论文信息
- 作者
- Wang X、Ren J、Wang Y、Luo M、Li J、He P
- 单位
- Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.China
- 文献类型
- 病例报告
- 期刊
- Frontiers in oncology2025
- 原文标识
- PubMed 40978033 · DOI 10.3389/fonc.2025.1656034
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →